Bard Associates Inc. Has $406,000 Holdings in Pro-Dex, Inc. (NASDAQ:PDEX)

Bard Associates Inc. grew its holdings in Pro-Dex, Inc. (NASDAQ:PDEX) by 17.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,596 shares of the medical instruments supplier’s stock after purchasing an additional 2,031 shares during the quarter. Bard Associates Inc. owned approximately 0.42% of Pro-Dex worth $406,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Perritt Capital Management Inc. grew its holdings in Pro-Dex by 43.3% during the 1st quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier’s stock worth $106,000 after acquiring an additional 1,813 shares during the period. Renaissance Technologies LLC grew its stake in shares of Pro-Dex by 7.9% during the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Pro-Dex by 5.1% during the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after purchasing an additional 3,067 shares during the period. Institutional investors and hedge funds own 15.28% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Ascendiant Capital Markets raised their target price on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a report on Monday. StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 7th.

Insider Activity

In related news, CFO Alisha Charlton sold 1,000 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $40.02, for a total value of $40,020.00. Following the transaction, the chief financial officer now owns 15,339 shares in the company, valued at $613,866.78. The trade was a 6.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 47.50% of the company’s stock.

Pro-Dex Trading Up 1.8 %

PDEX stock opened at $47.81 on Friday. Pro-Dex, Inc. has a one year low of $15.70 and a one year high of $49.98. The stock has a market cap of $155.86 million, a price-to-earnings ratio of 31.05 and a beta of 0.39. The company has a fifty day moving average price of $30.77 and a two-hundred day moving average price of $23.36. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings results on Thursday, September 5th. The medical instruments supplier reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.11. Pro-Dex had a net margin of 9.17% and a return on equity of 16.74%. The company had revenue of $15.03 million during the quarter. Equities analysts anticipate that Pro-Dex, Inc. will post 1.42 EPS for the current year.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.